Related Experiment Video
Updated: Jan 20, 2026
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Copper oxide nanoparticles inhibit pancreatic tumor growth primarily by targeting tumor initiating cells
Madeleine Benguigui1, Iris S Weitz2, Michael Timaner1
1Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, 31096, Israel.
Abstract:
Cancer stem cells, also termed tumor initiating cells (TICs), are a rare population of cells within the tumor mass which initiate tumor growth and metastasis. In pancreatic cancer, TICs significantly contribute to tumor re-growth after therapy, due to their intrinsic resistance. Here we demonstrate that copper oxide nanoparticles (CuO-NPs) are cytotoxic against TIC-enriched PANC1 human pancreatic cancer cell cultures. Specifically, treatment with CuO-NPs decreases cell viability and increases apoptosis in TIC-enriched PANC1 cultures to a greater extent than in standard PANC1 cultures. These effects are associated with increased reactive oxygen species (ROS) levels, and reduced mitochondrial membrane potential. Furthermore, we demonstrate that CuO-NPs inhibit tumor growth in a pancreatic tumor model in mice. Tumors from mice treated with CuO-NPs contain a significantly higher number of apoptotic TICs in comparison to tumors from untreated mice, confirming that CuO-NPs target TICs in vivo. Overall, our findings highlight the potential of using CuO-NPs as a new therapeutic modality for pancreatic cancer.
Insights
Copper oxide nanoparticles (CuO-NPs) show promise in treating pancreatic cancer by targeting cancer stem cells (CSCs). These nanoparticles effectively reduce CSC viability and induce apoptosis, inhibiting tumor growth in preclinical models.
Area of Science:
- Nanotechnology
- Oncology
- Cell Biology
Background:
- Cancer stem cells (CSCs), or tumor-initiating cells (TICs), drive tumor growth and metastasis.
- CSCs exhibit intrinsic resistance, leading to tumor re-growth after therapy, particularly in pancreatic cancer.
Purpose of the Study:
- To investigate the cytotoxic effects of copper oxide nanoparticles (CuO-NPs) on CSC-enriched pancreatic cancer cells.
- To evaluate the therapeutic potential of CuO-NPs against pancreatic cancer stem cells in vitro and in vivo.
Main Methods:
- Treatment of TIC-enriched PANC1 human pancreatic cancer cell cultures with CuO-NPs.
- Assessment of cell viability, apoptosis, reactive oxygen species (ROS) levels, and mitochondrial membrane potential.
- Evaluation of CuO-NP efficacy in a mouse model of pancreatic cancer.
Main Results:
- CuO-NPs demonstrated significant cytotoxicity against TIC-enriched PANC1 cells, decreasing viability and increasing apoptosis.
- Treatment with CuO-NPs led to elevated ROS levels and reduced mitochondrial membrane potential in cancer cells.
- CuO-NPs inhibited tumor growth in vivo and increased apoptosis in tumor-initiating cells within the tumors.
Conclusions:
- Copper oxide nanoparticles exhibit potent anti-cancer effects by targeting pancreatic cancer stem cells.
- CuO-NPs represent a potential novel therapeutic strategy for pancreatic cancer, addressing therapeutic resistance mediated by CSCs.
Related Concept Videos
07:02In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
04:11DCE-MRI of Orthotopic Pancreatic Tumor Xenografts: A Method to Assess Microvasculature in a Target Tumor Tissue
11:52Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:37In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells
06:16Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:57Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models